Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Safety and tolerability of fentanyl iontophoretic transdermal system: findings from a pooled data analysis of four clinical trials.

Minkowitz HS, Yarmush J, Donnell MT, Tonner PH, Damaraju CV, Skowronski RJ.

J Opioid Manag. 2010 May-Jun;6(3):203-10.

PMID:
20642249
2.

An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer.

Wright JC, Tao Leonard S, Stevenson CL, Beck JC, Chen G, Jao RM, Johnson PA, Leonard J, Skowronski RJ.

J Control Release. 2001 Jul 10;75(1-2):1-10.

PMID:
11451492
3.

Vitamin D and prostate cancer.

Feldman D, Skowronski RJ, Peehl DM.

Adv Exp Med Biol. 1995;375:53-63. Review.

PMID:
7645428
4.

Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.

Skowronski RJ, Peehl DM, Feldman D.

Endocrinology. 1995 Jan;136(1):20-6.

PMID:
7530193
5.
6.

Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.

Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D.

Cancer Res. 1994 Feb 1;54(3):805-10.

7.

Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.

Skowronski RJ, Peehl DM, Feldman D.

Endocrinology. 1993 May;132(5):1952-60.

PMID:
7682937

Supplemental Content

Loading ...
Support Center